Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma(LA HNSCC)

Brief Summary

Type:
Head and Neck Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03083873

Study #:
STUDY00142548

Start Date:
Jan 01, 0001

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03083873

View Complete Trial Details & Eligibility at ClinicalTrials.gov